Opportunities for Data Science in the Pharmaceutical Industry: The Use of Data to Find Efficiencies in Drug Development Can?t Come Too Soon

By the numbers, 2016 was not a good year for the U.S. pharmaceutical industry. As of early December, only 19 new drugs had been approved by the Food and Drug Administration (FDA), fewer than half of those approved in 2015 and the lowest number since 2007. Further, the FDA approved only 61% of submis...

Full description

Saved in:
Bibliographic Details
Published in:IEEE pulse 2017-05, Vol.8 (3), p.10-14
Main Author: Keshava, Nirmal
Format: Magazinearticle
Language:English
Subjects:
Clinical trials
Companies
Data science
Diseases
Drug development
Drug Industry
Drugs
FDA approval
Humans
Pharmaceutical industry
Pharmaceuticals
R&D
Regulatory agencies
Research & development
Return on investment
Statistics as Topic
United States
United States Food and Drug Administration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:By the numbers, 2016 was not a good year for the U.S. pharmaceutical industry. As of early December, only 19 new drugs had been approved by the Food and Drug Administration (FDA), fewer than half of those approved in 2015 and the lowest number since 2007. Further, the FDA approved only 61% of submissions in 2016, compared to 95% in 2015 [1]. And, among the largest companies, the return on investment for research and development (R&D) fell to 3.7% [2].
ISSN:2154-2287
2154-2317
DOI:10.1109/MPUL.2017.2678638